Kallyope Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 97

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $236M

  • Investors
  • 19

Kallyope General Information

Description

Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics thereby, providing users with an understanding of gut-brain biology that leads to transformational therapeutics for the improvement of human health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 430 East 29th Street
  • 10th Floor
  • New York, NY 10016
  • United States
+1 (646) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kallyope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 27-Jan-2022 $236M 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 25-Mar-2020 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 05-Dec-2018 $87M $131M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Dec-2015 $44M $44M 0000 Completed Generating Revenue
To view Kallyope’s complete valuation and funding history, request access »

Kallyope Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 43,454,779 $0.001000 8% $2 $2 1x $2 20.85%
Series A 44,050,000 $0.001000 8% $1 $1 1x $1 21.13%
To view Kallyope’s complete cap table history, request access »

Kallyope Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company'
Biotechnology
New York, NY
97 As of 2024
00000
00.000 0000-00-00
00000000000 00000

000000

do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cil
0000 000000000
Brisbane, CA
00 As of 0000
000.00
00000000000 000.00

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Cambridge, United Kingdom
00 As of 0000
000.00
00000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kallyope Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
Microbiotica Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
InterAx Venture Capital-Backed Villigen, Switzerland 00 00.000 00000 00000
Vium Formerly VC-backed San Mateo, CA 00 000.00 000000&0 000.00
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 000 00000 0000000000 0 00000
You’re viewing 5 of 26 competitors. Get the full list »

Kallyope Patents

Kallyope Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240115587-A1 Combination therapies Pending 24-Jun-2022 0000000000
EP-4320129-A1 Gpr119 agonists Inactive 06-Apr-2021 00000000
US-20240217983-A1 Gpr119 agonists Pending 06-Apr-2021 0000000000
AU-2021297323-A1 Ampk activators Pending 26-Jun-2020 00000000
US-11407768-B2 Ampk activators Active 26-Jun-2020 A61P1/00 000
To view Kallyope’s complete patent history, request access »

Kallyope Executive Team (17)

Name Title Board Seat Contact Info
James Galeota Jr. Chief Executive Officer, President & Board Member
Patrick Flanigan III Chief Financial Officer
Shirly Pinto Ph.D Chief Scientific Officer & Senior Vice President
Robert Barretto Ph.D Senior Director, BD & Competitive Intelligence Executive
Fernando Salles Ph.D Chief Business Officer
You’re viewing 5 of 17 executive team members. Get the full list »

Kallyope Board Members (10)

Name Representing Role Since
Amy Schulman JD Polaris Partners Board Member 000 0000
Franz Humer Self Chairman 000 0000
Jeffrey Goater The Column Group Board Member 000 0000
Joshua Wolfe Lux Capital Strategic Advisor & Board Member 000 0000
Nancy Thornberry Kallyope Founding Chief Executive Officer ,Chairman of Research and Development & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Kallyope Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kallyope Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bill Gates Angel (individual) Minority 000 0000 000000 0
DNS Capital Family Office Minority 000 0000 000000 0
Hartford Healthcare Endowment Limited Partner Minority 000 0000 000000 0
Mubadala Investment Company Sovereign Wealth Fund Minority 000 0000 000000 0
Parkwood Family Office Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Kallyope FAQs

  • When was Kallyope founded?

    Kallyope was founded in 2015.

  • Who is the founder of Kallyope?

    Charles Zuker Ph.D, Richard Axel MD, and Tom Maniatis Ph.D are the founders of Kallyope.

  • Who is the CEO of Kallyope?

    James Galeota Jr. is the CEO of Kallyope.

  • Where is Kallyope headquartered?

    Kallyope is headquartered in New York, NY.

  • What is the size of Kallyope?

    Kallyope has 97 total employees.

  • What industry is Kallyope in?

    Kallyope’s primary industry is Biotechnology.

  • Is Kallyope a private or public company?

    Kallyope is a Private company.

  • What is the current valuation of Kallyope?

    The current valuation of Kallyope is 00.000.

  • What is Kallyope’s current revenue?

    The current revenue for Kallyope is 00000.

  • How much funding has Kallyope raised over time?

    Kallyope has raised $479M.

  • Who are Kallyope’s investors?

    Bill Gates, DNS Capital, Hartford Healthcare Endowment, Mubadala Investment Company, and Parkwood are 5 of 19 investors who have invested in Kallyope.

  • Who are Kallyope’s competitors?

    Second Genome, Microbiotica, InterAx, Vium, and Vedanta Biosciences are some of the 26 competitors of Kallyope.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »